The study authors cited GLP-1-related weight loss and changes in nutritional status as risk factors for telogen effluvium, a type of non-scarring alopecia
The compound showed minimal muscle lossa major win for long-term metabolic health
NowPatient has taken all reasonable steps to ensure that all material is factually accurate, complete, and current
Research is needed to help illustrate the size and nature of access gaps so that we can design better coverage policies. Ultimately, there is a need for policymakers to recognize that factors unrelated to whether an individual has a medical necessity for treatment can affect whether or not a person is likely to receive these medications, says study lead author Meghan Podolsky (SPH24), research fellow in the Department of Global Health and an SPH alum who completed the MS program in epidemiology last year
Some studies have shown reductions in systemic inflammatory markers such as C-reactive protein (CRP) in patients taking GLP-1 medications, though whether this translates to clinically meaningful joint pain reduction independent of weight loss is not definitively established
Ambros Labs supplies Retatrutide to qualified researchers across Canada from our Canadian inventory
